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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
The aim is to assess, using network meta-analysis (NMA), the effectiveness and safety of interventions for preventing relapse-recurrence
of depression in adults in a primary care setting. NMA is a technique for comparing three or more interventions simultaneously in a single
analysis by combining both direct and indirect evidence across a network of studies.
The objectives are to:
1. estimate the relative effectiveness of pharmacological, psychological and other interventions to prevent relapse-recurrence, compared
with each other and controls (e.g. pill placebo, treatment as usual) on relapse-recurrence outcomes and adverse events;
2. assess the effect of interventions on quality of life outcomes and social and occupational functioning;
3. estimate the relative ranking of included interventions on relapse-recurrence, quality of life, and adverse events;
4. summarise availability and principal findings of eligible economic evaluations.
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B A C K G R O U N D
Description of the condition
Depression is now the leading cause of disability worldwide (WHO
2017), with a prevalence in excess of 264 million people globally
(GBD 2017). It results in significant morbidity for patients and exerts
a high societal and economic cost (Richards 2011). Rather than
being a phenotypically homogenous condition (i.e. presenting in
the same way in all people who experience depression), clinical
presentation and trajectories vary across patients. Some people
with depression experience a single, time-limited episode, and no
further episodes beyond that (Monroe 2011). Depression for others,
however, is a recurrent condition, with patients experiencing the re-
emergence (relapse or recurrence) of depressive symptoms aKer a
period of relative wellness (Beshai 2011). There is some evidence
to suggest that the risk of relapse and recurrence increases with a
greater number of depressive episodes experienced, but decreases
as the period of recovery gets longer (Beshai 2011; Solomon 2000).
The economic burden of depression is also significantly higher in
those who experience a relapse or recurrence compared to those
who do not (Gauthier 2019). Therefore, intervening to prevent
relapse and recurrence of depression is likely to improve the overall
course of illness for individual patients.
Relapse and recurrence of depression are usually defined with
respect to three further terms: response, remission and recovery.
According to most recent recommendations (Frank 1991; Rush
2006), response is an initial improvement of symptoms, usually
aKer treatment initiation and usually attributable to the treatment.
AKer three weeks of minimal symptoms, a patient can be said
to have entered remission. Any subsequent re-emergence of
depressive symptoms aKer this point is described as a relapse (a
return to the index episode of depression). If a relapse has not
occurred by four months aKer remission, a patient is said to have
entered recovery, aKer which point any re-emergence of depressive
symptoms is termed a recurrence (a new episode of depression
separate from the index episode).
The original description of relapse, recurrence and the other
change-points by  Frank 1991  presented a consensus view of
how these terms should be used to facilitate a more consistent
application in research. There is also probably a meaningful clinical
distinction to be made between a relapse back to the index
episode of depression before full recovery and the recurrence of
depression in the form of a new and discrete depressive episode,
following recovery. Subsequent efforts to validate the dichotomy
(or contrast between the two terms) have been few, but are
broadly supportive of the distinction (Beshai 2011; Riso 1997),
although the precise temporal cut-offs have not been empirically
derived and remain inconsistently operationalised in the literature
(Bockting 2015). Therefore, for the purpose of this review, we will
use the term 'relapse-recurrence', which has been used in previous
reviews of interventions (Cox 2012; Vittengl 2007), to mitigate
for inconsistencies in how the terms are applied in the included
studies.
The majority of work exploring the scope of the problem of
depressive relapse-recurrence has been done in secondary care
settings and is likely to be of limited applicability to primary care
(Buckman 2018), which is where the vast majority of patients with
depression are managed (Rait 2009). Relapse-recurrence rates, and
longer-term outcomes generally, tend to be worse in speciality
settings, compared to primary care settings (Ormel 2020). One
primary care cohort study that followed up people with remitted
depression found that 37.1% of participants relapsed within one
year (Lin 1998). It is worth noting that this study was relatively small
(n = 251) and followed up participants from randomised trials (all of
whom had been prescribed antidepressant medication); therefore,
this study's findings are potentially not generalisable to all primary
care populations. A more recent UK-based cohort study followed
up patients who had received low-intensity cognitive behavioural
therapy (CBT) through the Improving Access to Psychological
Therapies (IAPT) service of the UK National Health Service NHS.
Conducted in a community care setting, this study found that 53%
of participants experienced a relapse-recurrence within one year,
and that the majority (79%) of those participants did so within
the first six months (Ali 2017). This study is also not necessarily
representative of a typical primary care population, as not all
patients with depression in primary care would be referred to the
IAPT service.
Potentially more useful information can be gained from non-
clinical, naturalistic cohort studies. Two systematic reviews have
examined studies with naturalistic cohorts (Steinert 2014; Van
Weel-Baumgarten 2000). One review estimated primary care
relapse-recurrence rates to be between 30% and 40% (Van Weel-
Baumgarten 2000). The other review found that 35% to 60% of
participants experienced stable recovery (Steinert 2014). A study of
trajectories of depression in primary care suggests that the majority
of patients with depression in primary care follow a mild trajectory
of illness (Gunn 2013).
In addition to patients who experience single or recurrent episodes
of depression, there is a further group of patients who have
a more chronic and persistent form of depression. An estimate
from a review of naturalistic cohorts suggests that between
10% and 17% of depressed patients in primary care follow a
chronic rather than episodic course of illness (Steinert 2014). The
concepts of relapse and recurrence are less easily applied to
these patients, although this group of patients can include those
with recurrent depression, with incomplete remission between
episodes. Indeed,  Monroe 2011  cautioned against excluding
patients with chronic or persistent depression from studies of
relapse and recurrence; the majority of these patients do in fact still
remit or recover at times and can therefore be said to experience
a relapse and recurrence, despite the longer duration of index
episodes. In summary, the cohort of patients seen in primary care
is different from those in secondary care, and the studies discussed
here have limitations that prohibit us from making definitive
statements about relapse-recurrence rates in primary care settings.
Description of the intervention
There are three recognised treatment phases for depression:
treatments implemented before any symptomatic improvement,
with a view to achieving remission (acute phase); those employed
aKer symptomatic improvement but before recovery (continuation
phase); and those that extend past the point of recovery
(maintenance phase) (Bockting 2015). Interventions to prevent
relapse-recurrence might be targeted at patients who are in the
continuation or maintenance phases, having had symptomatic
improvement; or might be implemented during the acute phase,
with the intention of exerting a protective effect against relapse or
recurrence in the future (Bockting 2015).
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Pharmacological and psychological interventions are comparable
in terms of efficacy for acute phase depression (Cuijpers
2013; Kamenov 2016), and combination therapy is superior
to either type of intervention given singly (Kamenov 2016).
Like the acute phase interventions, interventions for preventing
relapse-recurrence of depression can broadly be considered
pharmacological (i.e. antidepressant medications (ADMs)) or
psychological. Other kinds of non-pharmacological therapies
might include social interventions (befriending, financial support),
service-level interventions (for example, collaborative care),
and combination interventions. Physical interventions such as
electroconvulsive treatment (ECT) can be used to prevent relapse in
some patients, although ECT is almost exclusively a secondary care
intervention, evidence for its efficacy is of low quality and there are
concerns around harm caused by ECT (NICE 2018).
There is reasonable evidence that compared with placebo, ADMs
prevent depression relapse-recurrence; there do not appear to
be major differences in this effect across different ADMs, or even
different classes of ADMs (Geddes 2003; Glue 2010; Hansen 2008;
Kaymaz 2008). A recent systematic review supported the pre-
existing evidence that compared to placebo, continuation of ADMs
for at least six months aKer remission significantly improved
relapse-recurrence rates, and that this was true for selective
serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants
(TCAs) and other newer agents (Kato 2020). Absolute benefits
from ADMs are greater for those at higher initial risk of relapse-
recurrence (Geddes 2003), and the effect may decrease aKer a
number of depressive episodes, as patients appear to develop
resistance to their prophylactic properties (Kaymaz 2008). There
are some limitations in the available literature around the effect of
ADMs on relapse-recurrence, which prevent us from drawing firm
conclusions about their effects in primary care populations. The
studies included in existing reviews have all been undertaken in
secondary care populations, where outcomes are generally poorer;
the included studies, on the whole, have not adjusted for potential
withdrawal effects upon stopping ADMs, which are likely to be a
significant confounding factor when estimating rates of relapse-
recurrence (Cohen 2010; Hengartner 2020; Recalt 2019). ADMs are
also not without their drawbacks:
• adverse effects are common (including sleep disturbance,
gastrointestinal disturbance and sexual dysfunction, among
others) (Van Leeuwen 2020), and can be worse in elderly people
(Coupland 2011);
• concerns about dependence and withdrawal symptoms (which
can oKen be confused with relapse, although these generally
occur much sooner aKer ADM discontinuation than relapse,
and can be severe and long-lasting (Davies 2019; Van Leeuwen
2020));
• reluctance by patients to take medication;
• poor concordance (i.e. not taking the medication as prescribed
or recommended); and
• high financial cost to the health service (Maund 2019).
The other issue with ADMs is that any prophylactic or protective
effects disappear when the medication is discontinued (Bockting
2015), whereas the effect from some types of psychological therapy,
like CBT and problem-solving therapy (PST), can endure beyond the
point at which the therapy is actually being administered (Cuijpers
2013; Vittengl 2007).
Psychological therapies for preventing relapse-recurrence include
CBT, mindfulness-based cognitive therapy (MBCT), PST, and
interpersonal therapy (IPT) (Clarke 2015). CBT aims to modify
thoughts and behaviours, such as reducing avoidance, increasing
activities and challenging negative thoughts. CBT also involves the
teaching of cognitive skills which focus on challenging underlying
dysfunctional beliefs (cognitive content) that can persist aKer
remission or recovery despite a non-depressed state, presenting a
vulnerability that might be more easily triggered by, for example,
life events or stress (Beshai 2011; Bockting 2015; Clarke 2015). MBCT
was developed specifically as an intervention to prevent relapse-
recurrence (Kuyken 2015) and, in addition to cognitive content,
also focuses on cognitive processes. MBCT teaches patients to
experience thoughts without judgement and to recognise that
negative thoughts are transient and do not have to guide feelings
or behaviours. IPT focuses on interpersonal and societal role
problems, which can be implicated in the onset and recurrence of
depressive symptoms (Clarke 2015).
The UK National Institute for Health and Care Excellence (NICE)
currently recommend that patients starting ADM for depression
should continue treatment for a minimum of six months aKer
remission to reduce the risk of relapse. People "at risk of relapse"
are advised to continue ADM for a minimum of two years (this
includes people who have had two or more episodes of depression,
have residual symptoms, have a history of severe or prolonged
episodes or inadequate response, or for whom "the consequences
of relapse are likely to be severe"). Recommendations for
relapse prevention psychological therapies are: individual CBT
for people who have relapsed despite ADM, or for people
with a significant history of depression and residual symptoms
despite treatment; and MBCT for patients who have had three
episodes or more of depression (NICE 2009). In more severe
cases, patients are usually referred for specialist treatment where
relapse prevention interventions can include further high-intensity
psychological treatment, lithium augmentation of ADM and ECT.
The Canadian Network for Mood and Anxiety Treatments (CANMAT)
depression guideline concurs with NICE that evidence to support
maintenance therapy for longer than two years is less well-
established, but that certain risk factors (early depression onset,
ongoing psychosocial adversity, older age, and comorbid medical
or psychiatric conditions) might justify extended maintenance
ADM treatment (Lam 2009). The American Psychiatric Association
(APA) guideline recommends continuation treatment with ADM
and depression-focussed psychological treatments. For those with
three or more previous depressive episodes, chronic depression
or other risk factors (including family history of mood disorder),
the APA advises maintenance treatment with the ADM treatment
that produced and maintained remission during the acute and
continuation phases, and for ECT to be considered beyond
that. They recommend regular monitoring for “signs of relapse”
throughout (Van Kempen 2010).
How the intervention might work
One route by which interventions for preventing relapse-
recurrence might work is through modifying neural pathways;
ADMs primarily exert their pharmacological effects on the
seratonergic, dopaminergic and noradrenergic pathways (Healy
1997). A comprehensive overview of these neurobiological
processes is beyond the scope of this review, but one mechanism by
which ADMs are thought to prevent relapse-recurrence through this
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route is by reducing the presence of residual depressive symptoms
(those that are sub-threshold and persist aKer remission), which
are strongly associated with increased risk of relapse-recurrence
(Buckman 2018; Lin 1998). While neurotransmitters are likely to be
implicated in some patients with depression, and modification of
these pathways is a sound theoretical basis for explaining some
of the effectiveness of ADMs at preventing relapse-recurrence, it is
widely accepted that depression is multifactorial. Indeed, a recent
study reports that for this reason, doctors increasingly avoid giving
overly simplistic biological explanations to patients (Tickell 2020).
Psychological therapies exert their effect by modifying a broader
range of therapeutic targets. Most psychological therapies for
preventing relapse-recurrence are designed to be provided during
the continuation or maintenance treatment phases; although, as
discussed, these can be given during the acute phase and exert a
longer-term benefit. As well as aiming to reduce residual depressive
symptoms (like ADMs) psychological therapies additionally target
cognitive and information processing mechanisms (specifically
those involved in integrating affective and cognitive information;
processing negatively valenced stimuli; social skills and the ability
to use social support; problem solving skills; and degree of
negative self-concept) and interpersonal stress pathways. Relapse
of depression is associated with negative thinking styles, such
as rumination (Buckman 2018). CBT specifically targets these
thoughts and aims to educate patients on how to modify and
transform such thoughts into more positive thoughts (Clarke 2015).
MBCT focusses on teaching patients to improve their awareness
of and relationship to such thoughts, rather than on modifying
the thoughts (Kuyken 2015). Psychological therapies also focus
on being aware of and planning for early warning signs of
relapse-recurrence, and also focus on healthy lifestyle behaviours.
In summary, there are a range of mechanisms by which the
interventions eligible for inclusion in this review might work to
improve relapse-recurrence outcomes.
Why it is important to do this review
We have discussed the burden associated with depression in
terms of patient morbidity and quality of life, as well as the
wider cost to society as a whole. Despite scientific progress and
an increased understanding of the biological and psychological
underpinnings of mental health conditions, there is no evidence of
a decrease in morbidity or mortality from depression, in contrast
to physical health conditions such as cardiovascular disease, stroke
and cancer (Insel 2009). Furthermore, the vast majority of people
with depression are managed in primary care (Ramanuj 2019),
yet the majority of research on depressive relapse-recurrence has
been undertaken in a secondary care context. There is a need for
feasible and scalable interventions that can be implemented in
a primary care clinical setting and, by better understanding what
interventions and intervention components work best, this review
could inform such efforts.
Other Cochrane Reviews have looked at similar interventions and
outcomes. One review assessed the effectiveness of continuation
and maintenance treatments for persistent depressive disorder,
mainly in a secondary care context (Machmutow 2019), and
found that the paucity and moderate/high risk of bias in the
available studies meant it was uncertain whether pharmacological
or psychological therapies were effective for preventing relapse-
recurrence.There has been a Cochrane Review of relapse
prevention interventions in children and adolescents (Cox
2012) and an ongoing review is exploring the effectiveness of
interventions aimed at teaching patients to recognise early warning
signs (EWS) of depression to prevent recurrence (Lenora 2019).
These will form part of a larger body of evidence looking at relapse
prevention more generally.
There has been only one previous systematic review of relapse
prevention strategies, specifically in a primary care setting (Gili
2015); this review identified only three studies. There have
been a number of new primary care-based RCTs of relapse
prevention interventions since the publication of that review. A
synthesis of available evidence is needed to guide the allocation
of interventions in primary care to prevent relapse-recurrence
and improve disease trajectories for patients. As we have seen,
it is not well understood which interventions work best for
which patients, and national guidelines differ in terms of risk
stratification and treatment recommendations. This speaks to the
fact that depression is complex and centred in a biopsychosocial
context. Furthermore, there are multiple kinds of interventions
available. Patient preferences and individual patient circumstances
will always be important in guiding treatment decisions through
discussion with healthcare professionals. An ability to be able to
inform patients about the relative effectiveness of the  range of
different treatment options is an essential part of this decision-
making process. This review aims to provide a robust summary of
the available evidence to support such discussions.
O B J E C T I V E S
The aim is to assess, using network meta-analysis (NMA), the
effectiveness and safety of interventions for preventing relapse-
recurrence of depression in adults in a primary care setting.
NMA is a technique for comparing three or more interventions
simultaneously in a single analysis by combining both direct and
indirect evidence across a network of studies.
The objectives are to:
1. estimate the relative effectiveness of pharmacological,
psychological and other interventions to prevent relapse-
recurrence, compared with each other and controls (e.g. pill
placebo, treatment as usual) on relapse-recurrence outcomes
and adverse events;
2. assess the effect of interventions on quality of life outcomes and
social and occupational functioning;
3. estimate the relative ranking of included interventions on
relapse-recurrence, quality of life, and adverse events;
4. summarise availability and principal findings of eligible
economic evaluations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all RCTs (including cluster- and cross-over RCTs)
that include direct comparisons between two or more eligible
interventions and/or usual care, control or placebo. The latter
are useful for NMA, as placebo can be a common comparator
and therefore can be an important component of a network of
interventions. All studies must have taken place in a primary
care or community setting. A primary care setting is the first
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point of contact for a patient accessing health services (e.g.
in a general practitioner's clinic) and interventions are usually
delivered by a generalist. By community settings, we mean
interventions delivered outside of a traditional primary care setting
(e.g. those delivered in community centres or community clinics)
but not requiring a specialist referral to a secondary care setting.
Community settings include nursing and residential care settings,
as long as there is no specialist or secondary care involvement.
Services providing first-line psychological treatments (for example,
the UK’s IAPT service (Clark 2011)) are also oKen termed community
rather than primary care, and their cohorts are likely to be directly
applicable to a primary care setting. These will be all included, but
setting (primary or community care) will be explored as a potential
source of heterogeneity.
Types of participants
Adults (age 18 years and over) with major depressive disorder
(MDD), diagnosed in line with Diagnostic and Statistical Manual
of Mental Disorders (DSM-V) criteria, either through diagnostic
interview or using a validated diagnostic questionnaire, who have
entered remission or recovery before receiving the intervention.
Participants with remission or recovery would be defined as those
patients who had met diagnostic criteria for MDD at baseline but
no longer met these diagnostic criteria.  In this review, we will
not include interventions delivered during the acute phase of
depression. It is likely that the majority, if not all, of the included
studies will have tested interventions in participants with recurrent
depression.
We will not include participants with severe mental illness
(for example, bipolar affective disorder or schizophrenia), as
these participants would not represent a population comparable
with those with only MDD and therefore would be a potential
threat to the transivity assumption (similarity of the direct and
indirect evidence) of the network meta-analyses. We will include
participants with other psychological co-morbidities which are
routinely managed in primary care (for example, anxiety, post-
traumatic stress disorder, obsessive-compulsive disorder). We will
also include participants with physical co-morbidities and long-
term conditions, and will explore this as a potential source of
heterogeneity if appropriate to assess whether this may contribute
to intransitivity. In addition, criteria for comparing the similarity
of participant characteristics of included studies is outlined in
"Assessment of clinical and methodological heterogeneity within
treatment comparisons" below.
Types of interventions
RCTs of any intervention specifically aimed at preventing relapse
or recurrence of depression in a primary or community care
setting. These could be pharmacological, psychological or social
(e.g. collaborative care, community outreach, befriending). We
expect that some RCTs may compare different interventions (e.g.
psychological versus pharmacological approach) rather than a
control arm. As discussed, physical therapies such as ECT are not
relevant to a primary care setting and therefore will be excluded
from this review.
The following are interventions of clinical relevance (decision-set
interventions).
• Pharmacological interventions: Previous reviews have not
suggested significant differences in the effectiveness of different
ADMs on relapse and recurrence across primary and secondary
care settings, but there may be a dose-related effect (Hansen
2008). Where different doses or drug classes have been trialled,
we will merge classes (e.g. SSRI, TCA, serotonin-norepinephrine
reuptake inhibitor (SNRI)) and will split these by dose (low,
medium and high strength), according to equivalent doses per
the British National Formularly.
• Psychological interventions will be categorised by type (for
example: CBT, MBCT, IPT), and intensity (for example, high-
versus low-intensity CBT, as defined by the authors of primary
studies). Group and individual psychological interventions will
be treated a separate nodes in the NMA.
• Other interventions: as discussed, interventions that aim
to prevent relapse-recurrence, but which are not either
pharmacological or psychological will be included, as long as
they meet the other inclusion criteria.
The following are supplementary-set interventions and are
included to give greater power and to connect up the network, but
are not themselves of clinical relevance:
• Placebo, control, or 'treatment as usual' arms. These can be
defined as deemed appropriate by the trial authors. We will
extract information about the content of these arms to ensure
that they are directly comparable.
Types of outcome measures
Primary outcomes
• Time to relapse-recurrence
Time to relapse-recurrence provides a more detailed picture of
intervention effectiveness than a binary outcome (i.e. relapse-
recurrence or no relapse-recurrence). We will define participants
with relapse-recurrence as those who had previously met the
definition for remission or recovery but subsequently met the
diagnostic criteria for MDD.
The primary harm outcome is adverse events (for example,
discontinuation due to side effects, self-harm, suicide, or
hospitalisation).
Secondary outcomes
• Binary relapse-recurrence outcome
• Antidepressant medication dose changes (change in dose aKer
intervention, to enable us to assess whether interventions led to
increased or decreased ADM prescription)
• Quality of life measures (e.g. EQ-5D, SF-36, or any other
instrument)
• Social and occupational functioning (e.g. Global Assessment of
Function Scale (GAF), Occupational Functioning Scale (OFS), or
any other instrument)
Timing of outcome assessment
We will analyse outcome data at the following time points: short-
term (less than six months), medium-term (six to 12 months) or
long-term (greater than 12 months).
Hierarchy of outcome measures
Due to the great likelihood of more than one reported eligible
outcome, we will include data as per the following rules.
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• In case of available data from both observer-rating scales
and self-report questionnaires, we will prioritise data from
observer-rating scales. For the remission/recovery and relapse-
recurrence  outcomes, we will give preference to diagnostic
interview or HAM-D and for the self-reporting scale, we will give
preference to the PHQ-9 or BDI.
• In case of several outcome measures of the same hierarchy level
used in one trial, we will select the outcome measure most
frequently used across all trials.
• In case of several outcome measures of the same hierarchy level
and the same availability across trials, we will randomly select
the outcome measure.
• Where applicable, if diagnostic interview, HAM-D or BDI were not
reported, we will select the outcome measure most frequently
used across all trials.
Economic commentary
We will develop a brief economic commentary based on current
methods guidelines (Aluko 2020) to summarise the availability and
principal findings of trial-based full economic evaluations (cost-
effectiveness analyses, cost-utility analyses, cost-benefit analyses)
that compare psychological or pharmacological relapse prevention
interventions with each other or with controls for depression. This
commentary will focus on the extent to which principal findings
of eligible economic evaluations indicate that an intervention is
judged favourably (or unfavourably) from an economic perspective,
when implemented in different settings. A separate search will
be conducted to identify economic evidence, including: screening
the reference lists and conducting forward citation tracking from
eligible studies of effects identified for inclusion in the main review;
a search of NHS Economic Evaluation Database (NHS EED); and
the use of specialist search filters to sets of records retrieved by
searches of one or two selected general electronic biomedical
literature databases searched for the main review of intervention
effects (as recommended by the Cochrane Economics Methods
Group).
Identified economic evaluations will be screened against the
inclusion criteria by one review author (ASM). Data will be extracted
including: basic details of the characteristics of each identified
economic evaluation (including analytic framework and type of
economic evaluation, analytic perspective and time horizon, main
cost items included in each analysis, and setting); and brief text
extracts that summarise their principal findings (verbatim text on
conclusions drawn by the authors of each economic evaluation and
text that summarises uncertainty surrounding authors’ principal
conclusions).
The findings of the brief economic commentary will be
incorporated into the 'Discussion' section and will include a brief
narrative summary of: the electronic health economics literature
databases searched; the number of relevant economic evaluations
identified for each eligible comparison (each eligible intervention/
comparison combination); the descriptive information collected
from each study; principal conclusions as reported by the authors of
each analysis (with respect to the base case analysis); and principal
sources of uncertainty regarding authors’ principal conclusions
(based on the results of any sensitivity analyses conducted).
Search methods for identification of studies
Electronic searches
An Information Specialist with the Cochrane Common Mental
Disorders Group (CCMD) will run searches on the following
bibliographic databases and trial registers using relevant subject
headings (controlled vocabularies) and search syntax, appropriate
to each resource.
• Cochrane Common Mental Disorders Controlled Trials Register
(CCMDCTR) (all available years).
• The Cochrane Central Register of Controlled Trials (CENTRAL)
(the Cochrane Library, latest issue).
• Ovid MEDLINE (1946 to date) (Appendix 1).
• Ovid Embase (1974 to date).
• Ovid PsycINFO (all available years).
• ISI Web of Science: Conference Proceedings Citation Index-
Science (CPCI-S) (1990 to date).
• ClinicalTrials.gov (www.clinicaltrials.gov) (all available years).
• World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/) (all available years).
There will be no restrictions on date, language or publication status
applied to the searches.
Searching other resources
The Information Specialist will also search the following sources of
grey literature (primarily for dissertations and theses).
• Open Grey (www.opengrey.eu).
• ProQuest Dissertations & Theses Global (www.proquest.com/
products-services/pqdtglobal.html).
• DART-Europe E-theses Portal (www.dart-europe.eu).
• EThOS - the British Libraries e-theses online service
(ethos.bl.uk).
• Open Access Theses and Dissertations (oatd.org).
Reference lists
We will check the reference lists of all included articles and relevant
systematic reviews to identify additional research missed from the
original electronic searches (e.g. ongoing studies, unpublished or
in-press citations).
Personal communication
We will contact authors and subject experts for information on
unpublished or ongoing studies, or to request additional data.
Data collection and analysis
Selection of studies
All abstracts will be independently screened by two review authors
(from among AM, LR, FM, NC), with any disagreements to be
referred to a third review author (NM). The same process will apply
to full-text screening. We will identify and exclude duplicate records
and we will collate multiple reports that relate to the same study,
so that each study, rather than each report, is the unit of interest in
the review. We will record the selection process in sufficient detail
to present an adapted PRISMA flow chart of study selection and
‘Characteristics of excluded studies' table.
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Data extraction and management
We will extract data using a pre-prepared and pre-piloted data
collection form. Two review authors (from among ASM, LR, FM,
NC) will independently extract data, and any disagreements
or discrepancies will be resolved by referral to a third review
author (NM). We will extract the following study intervention and
population characteristics that may act as effect modifiers:
• methods: study design, total duration of study, number of study
centres and location, study setting (primary care, community),
withdrawals, and date of study;
• participants: number, mean age, age range, gender, baseline
severity of condition, diagnostic criteria, number of previous
episodes, length of index episode, recurrence status, anxiety
symptoms; inclusion criteria, and exclusion criteria, suicide-
related behaviours; level of suicide ideation; risk of suicide; co-
morbid chronic physical illness, psychiatric co-morbidity; socio-
economic status;
• interventions: type and duration of acute phase intervention;
type of relapse-recurrence prevention intervention;
comparison; dose (including intended and actual dose
received); duration of treatment; concomitant medications;
concomitant psychosocial interventions (including type,
duration, who delivered the intervention, whether it was
delivered to groups or individuals, was manualised, actual
number of sessions attended); and excluded medications;
• outcomes: primary and secondary outcomes specified and
collected, and time points reported;
• notes: funding for trial, and notable conflicts of interest of trial
authors.
Outcome data
We will extract from each included study arm-level data about
relapse-recurrence rates and time to relapse-recurrence, the
duration of the intervention, the number of participants, the
drop-out rates, the authors’ definition of relapse-recurrence, the
number of patients that experienced a relapse-recurrence and the
interventions being compared. When extracting data about type
and duration of acute phase interventions, we will also extract
information about how the individual studies have controlled for
withdrawal confounding (Hengartner 2020).
Other data
We will extract and report a narrative summary of any cost-
effectiveness analyses taking place alongside the RCT. If outcome
data are not reported in a usable way (e.g. missing standard
deviations (SD) or 95% confidence intervals (CIs)), we will note this
in the ‘Characteristics of included studies' table. We will resolve
disagreements by consensus or by involving a third review author
(NM). One review author (ASM) will transfer data into the Review
Manager 5.4 file (Review Manager 2020) or RevMan Web (RevMan
Web 2019). We will double-check that data are entered correctly by
comparing the data presented in our review with the study reports.
A second review author (from LR, FM or NC) will spot-check study
characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (ASM, LR, FM, NC) working independently will
undertake risk of bias assessment, using version 2 of the Cochrane
risk of bias tool for randomised controlled trials (RoB 2) (Higgins
2021; Sterne 2019), with respect to effect of assignment. We will
do this for the two primary outcomes (time to relapse-recurrence
within 12 months; adverse outcomes at any timepoint). A third
review author will resolve any disagreements. We will use the
methods described in the ROB 2 guidance for Cluster RCTs. We will
assess the risk of bias according to the following domains:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other bias.
We will judge each potential source of bias as either high, low or
unclear, and will provide a supporting quotation from the study
report together with a justification for our judgment in the ‘Risk of
bias' table. We will summarise the ‘Risk of bias' judgements across
different studies for each of the domains listed. We will use the RoB2
excel tool to manage assessments and will store documentation
of judgements and assessments on a data repository website for
scientific data, where they will be available to readers of the full
review. Where necessary, we will contact the trial authors for
further information. Where information on risk of bias relates to
unpublished data or correspondence with a trial author, we will
note this in the ‘Risk of bias' table. We will present all ‘Risk of bias'
data graphically and in the text.
Measures of treatment effect
Relative treatment effect
Where time to relapse-recurrence has been assessed, we will use
hazard ratios (HRs). We will express dichotomous outcome data
as risk ratios (RRs) with 95% CIs. We will express continuous data
as standardised mean differences (SMD) with 95% CIs. To aid
interpretation of SMDs we will back-transform estimates to the
most commonly reported scale for that outcome. Results from the
NMA will be presented as summary relative effect sizes (SMD or RR)
for each possible pair of treatments.
Relative treatment ranking
Where appropriate, we will also estimate the ranking probabilities
for all treatments of being the most effective treatment using P
values, which take into account effect estimates and precision
(Chaimani 2020). However, if we identify too much uncertainty we
will not rank treatments.
Unit of analysis issues
Cluster-randomised trials
Cluster-RCTs involve the randomizsation of participants as groups
(or clusters) rather than as individuals. If we include cluster-RCTs,
but reported data have not been appropriately adjusted for the
correlation between participant outcomes within clusters, we will
contact trial authors to obtain an estimate of the intra-cluster
correlation coefficient (ICC); or impute the ICC using estimates
from the other included trials, or from similar external trials. We
will inflate the reported standard errors by the square root of the
design effect, using the estimated/imputed ICC (Higgins 2020). We
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will undertake sensitivity analyses to assess the robustness of the
combined intervention effects to assumptions regarding the ICCs.
Cross-over trials
If we include cross-over trials (trials where participants receive a
sequence of different interventions), we will only use data from the
first cross-over period, due to the risk of carry-over effects.
Studies with multiple treatment groups
For multi-arm trials, we will use graph-theoretical methods (using
the R soKware package 'netmeta', R) to account for between-arm
correlations. The netmeta package treats multi-arm trials as a
complete subgraph with known variances. For each comparison
within the trial, variances are back-calculated adjusting for
correlation between arms (Rucker 2012).
Dealing with missing data
We will attempt to obtain any missing data (data necessary for our
analysis that is not reported in the trial paper) from study authors.
If we are unable to obtain missing SDs from study authors, we will
estimate these from P values, t-statistics, CIs or standard errors, if
reported in the paper.
If a vast majority of SDs are available and only a minority of SDs are
unavailable or unobtainable, we plan to use the method devised by
Furukawa and colleagues to impute SDs and calculate percentage
responders (Furukawa 2005; Furukawa 2006). If we use this method,
we will interpret data with caution and will take into account
the degree of observed heterogeneity. We will also undertake a
sensitivity analysis to examine the effect of the decision to use
imputed data.
If additional figures are not available or obtainable and it is not
deemed appropriate to use the Furukawa method as described
above, we will not include the trial data in the comparison of
interest.
We will pool 'last observation carried forward' (LOCF) data and
other data from other imputation methods, such as multiple
imputation or mixed effect models (rather than mix LOCF and
observed case (OC) data). We will also undertake sensitivity
analyses using OC data, where available.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity within
treatment comparisons
Heterogeneity and transitivity are related. Heterogeneity results
from variation of effect modifiers within a treatment comparison,
while intransitivity results from variation of effect modifiers across
treatment comparisons (EKhimiou 2016). To evaluate the presence
of clinical heterogeneity we will generate and compare descriptive
statistics for trial and study population characteristics across all
eligible trials that compare each pair of interventions.
When we find heterogeneity, we will attempt to determine
potential reasons for it by examining individual study and
subgroup characteristics. We expect the following characteristics to
potentially introduce clinical heterogeneity and intransitivity.
• Study setting (primary care or community).
• Type of depression (first-episode; recurrent; chronic).
• Age of participants.
• Comorbid anxiety.
• Physical comorbidity (long-term conditions).
• Gender.
• Socio-economic status.
• Length of follow-up/timing of relapse.
• Dose of treatment (e.g. milligram dosage of ADMs, length and
number of sessions with for psychological interventions).
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In NMAs, we will assume a common estimate for the heterogeneity
variance across the different comparisons.
Measures and tests for heterogeneity
We will assess statistical heterogeneity using the I2 statistic
and its 95% CI and Tau2 (between-study variance). I2 quantifies
heterogeneity across studies by measuring the percentage of
variability that cannot be attributed to random error. The Cochrane
Handbook for Systematic Reviews of Interventions provides the
following rule of thumb for interpreting I2 values (Deeks 2020):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
The I2 will be interpreted in light of its magnitude and direction of
effects and the strength of evidence for heterogeneity (width of 95%
CI).
Assessment of transitivity across treatment comparisons
As described, transitivity assessment is related to heterogeneity
assessment, with transitivity being specifically applicable to NMA
and relating to differences in the distribution of different effect
modifiers across different comparisons. We will assess transitivity
by comparing the distribution of effect modifiers across the
different comparisons for each outcome.
Assessment of statistical inconsistency
Inconsistency (also called incoherence) is the statistical
manifestation of intransitivity in the data. Inconsistency occurs
when direct and indirect evidence for a particular relative effect
are in disagreement, and is only possible to detect when there are
evidence loops (sources of direct and indirect evidence for the same
comparison).
Local approaches for evaluating inconsistency
Local approaches focus on a particular comparison and usually
involve assessing the absolute difference between the two
summary estimates in the form of an inconsistency factor (IF). We
will use a loop-specific approach (a loop of evidence is formed
when at least three pairs of treatments have been compared and
form a closed path). An IF will be calculated by contrasting direct
estimates with indirect estimates. The magnitude of the IFs, their
95% CIs and a loop-specific Z-test will be used to infer about the
presence of inconsistency in each loop. We will extend analysis to all
closed loops assuming a loop-specific heterogeneity and examine
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the estimates of inconsistency together with 95% CIs for each
loop, using a graphical representation. We will assume a common
heterogeneity estimate within each loop and will be cautious
deriving conclusions from this approach. Netmeta soKware also
provides pairwise meta-analyses estimates as part of the analyses
and we will informally compare these estimates with the results
found in our network meta-analyses.
Global approaches for evaluating inconsistency
We will also perform a global assessment of inconsistency to
check the assumption of consistency in the entire network. We
will model inconsistency using the design-by-treatment interaction
model (Higgins 2012), which accounts for different source of
inconsistency that can occur when studies with different designs
(two-arm trials versus three-arm trials) give different results as well
as disagreement between direct and indirect evidence.
Assessment of reporting biases
We will use a framework described in the Cochrane Handbook (Page
2019) that proposes an assessment be made for each comparison
regarding the risk and potential impact of missing data from studies
("known-unknowns") and risk of missing studies ("unknown-
unknowns"). We will use this framework in our GRADE assessments
to guide our judgements on ‘undetected’ or ‘suspected’ reporting
bias .
For our primary outcome, we will be guided by our risk of bias
assessments, as well as by comparison-adjusted funnel plots
(extensions of funnel plots for use in network meta-analyses), if
there are a minimum of ten studies (Chaimani 2012). Where there
is evidence of funnel plot asymmetry, we will adjust for small-study
effects using WinBUGS/OpenBUGS (Mavridis 2016).
Data synthesis
Assuming that we have a connected network of treatments, we will
perform NMAs using the netmeta package in R for all outcomes.
Feasibility will be assessed in terms of the number of data points,
heterogeneity of treatment and outcome characteristics as well
as the patient and study characteristics (Cipriani 2013).  We will
illustrate network geometry using network plots. If we identify
relevant interventions that we are not aware of at the Protocol
stage, we will consider them as eligible and we will include them
in the network aKer assessing their comparability with the pre-
specified set of competing interventions. They will be included in
the meta-analysis so long as they fulfil the transitivity assumptions
as follow: that they are in principle jointly randomisable along
with the other included interventions (that is, they have the same
indication and could be meaningfully compared head-to-head with
one another). We will also include contour-adjusted funnel plots
for our primary outcomes to assess the potential impact of small
studies on findings, if there are 10 or more included studies in these
analyses.
Subgroup analysis and investigation of heterogeneity
If we find important heterogeneity or/and inconsistency (see
above), we will explore the possible sources. If sufficient studies
are available, we will also perform an NMA with meta-regression
analyses on the primary outcome in Stata (Stata) for the following
factors.
• Study setting (primary or community).
• Type of depression (first-episode; recurrent; chronic), as defined
by the authors.
• Age of participants (< 65 years and > 65 years).
• Comorbid anxiety (presence or absence, using an appropriate
validated instrument, e.g. GAD-7).
• Length and number of sessions for psychological interventions.
• Funded by pharmaceutical company (yes or no).
Sensitivity analysis
We will undertake sensitivity analyses for the primary outcomes to
investigate how effect estimates are affected by the following.
• Definition of relapse/recurrence: we will assess effects only in
recurrent depression (i.e. exclude studies focusing on a single
episode of depression).
• Drug classes: as there may be heterogeneity within drug classes
we will also conduct NMAs including individual drugs as nodes.
• Dose: our primary analyses propose to include different doses
as separate nodes in the network, we will assess the impact of
combining doses of the same drug as a single node.
• Study bias: we will perform a sensitivity analysis excluding all
studies assessed to be at high overall risk of bias and comparing
the results.
• Provided there is sufficient information in the primary studies,
we will compare relapse-recurrence rates in those studies that
adequately controlled for withdrawal confounding (those that
continued acute phase pharmacological management or those
that documented this was weaned appropriately (NICE 2009)),
versus those that did not (i.e. where ADM was stopped abruptly
prior to the relapse prevention intervention, or where the
approach was not documented)).
• Missing data: we will conduct analyses including analyses with
OC data in addition to LOCF and other imputed data.
Summary of findings and assessment of the certainty of the
evidence
We will present 'Summary of findings' tables, based on the
template provided in Table 2 in  Yepes-Nunes 2019  (but we will
not report a column for ranking and will include a column for
comments), for the following primary outcomes:
1. Time to relapse-recurrence (within 12 months)
2. Adverse outcomes (at any timepoint)
The 'Summary of findings' tables will include all interventions.
For the relapse-recurrence related outcomes (time to relapse-
recurrence or binary outcome), we will assess our certainty in
the evidence from the NMA using the Confidence In Network
Meta-Analysis (CINeMA) approach (CINeMA; Nikolakopoulou 2020;
Papakonstantinou 2020). CINeMA is based on the GRADE framework
for assessing the certainty of the body of evidence and involves
assessing the following six domains: within-study bias (i.e. the
impact of risk of bias of the included trials); reporting bias (i.e.
the impact of missing studies, outcomes and results); indirectness;
imprecision; heterogeneity; and incoherence. Each domain (except
'reporting bias') is judged to have no concerns, some concerns
or major concerns. 'Reporting bias' is judged as 'suspected' or
'undetected'. Judgements across the six domains are summarised
to obtain four levels of confidence for each relative treatment effect:
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very low, low, moderate or high. We will assess our certainty in
all comparisons formed by treatment groups in the decision and
supplementary sets. Here we provide some further detail of the
criteria we will use to inform our judgements for the domains.
Within-study bias
This domain concerns risk of bias within the included studies.
In judging the certainty of the evidence for each relative
effect estimate in this domain, we will consider the percentage
contribution from studies judged to be at a low risk of bias, with
some concerns, or a high risk of bias. Specifically, we will calculate
a weighted average of the risk of bias, where the risk of bias
judgements are assigned scores of −1 (low), 0 (some concerns) and 1
(high), and these scores are weighted by the proportion contributed
from studies at each level. We will use these weighted averages to
classify the certainty of evidence for each estimate. We may choose
to override some of the judgements based on the findings from our
sensitivity analysis that excludes trials at a high risk of bias.
Indirectness
In judging the certainty of the evidence for each relative effect
estimate in this domain, we will consider for each study how
directly it addresses the research question in combination with
the percentage contribution the study makes to the estimate. In
considering directness, we will consider population, intervention
and outcome characteristics that are potential effect modifiers (e.g.
age).
Reporting bias
We will use the results from our investigation of reporting bias (see
'Assessment of reporting biases', above) in judging the certainty
of evidence for each relative effect estimate. This will involve
considering the contribution that each direct comparison makes to
each relative effect estimate (i.e. network estimate).
Imprecision
In judging the certainty of the evidence for each relative effect
estimate in this domain, we have set a “margin of equivalence”
for relapse-recurrence outcomes. The margin of equivalence
corresponds to clinically unimportant differences between groups.
Our margin of equivalence for relapse-recurrence outcomes
corresponds to a risk ratio of between 0.8 and 1.25. We have derived
this by assuming a comparator risk of 0.5, based on expected
baseline relapse rates, and a risk difference of 0.1, based on
agreement among the research team that a 10% improvement
would be clinically meaningful in this cohort.
Heterogeneity
We will use the clinical equivalence ranges specified for the
'imprecision' domain in combination with prediction intervals, to
determine whether heterogeneity in the results affects our certainty
in the evidence.
Incoherence
We will take into account both global and local approaches
to inconsistency. For local approaches, we will use the clinical
equivalence ranges specified for the 'imprecision' domain in
combination with the 95% CIs of direct and indirect relative
treatment effects to determine if incoherence between these
estimates affects our certainty in the evidence.
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Appendix 1. MEDLINE search strategy






3 Depressive Disorder, Major/
4 Depressive Disorder, Treatment-resistant/
5 depress*.ti.
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6 (depress* adj5 (relaps* or recurr* or maintenance or continuation or prophyla*)).ti,ab,kf,kw.
7 (depress* adj5 (chronic* or clinical* or diagnos* or disorder* or major or unipolar or illness or resistan* or refractory or scale* or score*




10 Secondary Prevention/ or Tertiary Prevention/
11 *Preventive Health Services/
12 ((prevent* or reduc*) adj5 (future or repeat* or relaps* or recurr* or secondary or tertiary or target* or indicat*)).ti,ab,kf,kw.
13 ((time or timing) adj2 (relaps* or recurr*)).ti,ab,kf,kw.
14 ((continuation or maintenance) adj2 (treatment* or therap* or psycotherap* or phase or antidepress* or anti-depress* or
medicat*)).ti,ab,kf,kw.
15 or/9-14
16 (8 and 15)
17 depress*.ti. and ((relapse or recurr* or maintenance or continuation or prophyla*) adj5 (recovered or remission or remit* or responder*
or "responded to" or recent* or previous* or past)).ti,ab,kf,kw.
18 (16 or 17)
[RCT Filter]
19 controlled clinical trial.pt.
20 randomized controlled trial.pt.
21 clinical trials as topic/
22 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf.
23 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster or crossover or cross-over or control* or




26 (control* adj3 group*).ab.
27 (control* and (trial or study or group*) and (waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kf,kw,hw.
28 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,kf,kw.
29 double-blind method/ or random allocation/ or single-blind method/
30 or/19-29
31 exp animals/ not humans.sh.
32 (30 not 31)
33 (18 and 32)
[Primary Care Filter]
34 Primary Health Care/ or "Continuity of Patient Care"/ or Patient Handoff/ or Transition to Adult Care/
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35 Physicians, Family/
36 General Practice/ or Family Practice/
37 *Family Health/
38 (primary adj2 (care or health*)).ti,ab,kf,kw.
39 (GP or "GP’s" or generalist*).ab.
40 ((general or family or nurs*) adj1 (practice* or practitioner*)).ti,ab,kf,kw.
41 Nurse Practitioners/
42 Primary Care Nursing /
43 Family Nursing/
44 Home Nursing/
45 Community Health Centers/ or Community Mental Health Centers/
46 (homecare or home care or (care adj3 community)).ti,ab,kf,kw.
47 ((family or community or practice*) adj (medic* or doctor* or physician* or health* or nurs*)).ti,ab,kf,kw.




52 (("Access to Psychological Therapies" or IAPT) or (psych* adj3 practitioner*)).ti,ab,kf,kw.
53 or/34-52
54 (33 and 53)
***************************
Appendix 2. Glossary of terms
Recovery: follows an extended period of remission; at this point, patients are said to be no longer in episode.
Recurrence: a new episode of depression, separate from the index episode.
Relapse: a return to the index episode of depression.
Relapse-recurrence: a hybrid term used to describe the re-emergence of depressive symptoms aKer a period of relative wellness, to account
for inconsistencies in how relapse and recurrence are operationalised in the literature.
Remission: a period of time, following a response to treatment, during which patients have minimal depressive symptoms but are still “in
episode”.
Response: an initial improvement of symptoms, usually aKer treatment initiation and usually attributable to the treatment.
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